Navigation Links
Study finds key link responsible for colon cancer initiation and metastasis
Date:11/11/2013

Chronic inflammation has long been known as a key risk factor for cancer---particularly colon cancer---but the exact mechanisms of how inflammation heightens the immune response, and ultimately influences the initiation and progression of cancer have remained elusive. It is well established that anti-inflammatory drugs, like aspirin, reduce the risk of colorectal cancer.

Now, an ASU research team led by Biodesign Institute executive director Dr. Ray DuBois, M.D., PhD, has shown that a key genetic culprit, called CXCR2, is implicated in the tumor formation, growth and progression in a mouse model of colon cancer.

"We have been trying for the past several years to understand the precise molecular links between inflammation and cancer, said DuBois. "We have demonstrated that CXCR2 mediates a critical step in the setup of the blood circulatory machinery that feeds tumor tissue. This provides an important new clue for the development of therapeutic targets to neutralize the effect of CXCR2 on colon cancer."

The DuBois' Laboratory for Inflammation and Cancer, which includes lead author Hiroshi Katoh, and colleagues Dingzhi Wang, Takiko Daikoku, Haiyan Sun, and Sudhansu K. Dey, published the results in the November 11 issue of Cancer Cell.

The results provide critical new clues toward the prevention of colorectal cancer, the second leading cause of cancer deaths in the U.S. Despite the availability of colonoscopy screening, the 5-year survival rate remains low, due to a large number patients presenting with advanced stages of the disease. Currently, there are no clinically available blood tests for the early detection of sporadic colon cancer.

Inflammation has long been associated with increasing one's risk for colon cancer. For instance, more than 20 percent of patients with a form of inflammatory bowel disease (IBD) develop colorectal cancer within 30 years of diagnosis. This colitis-associated cancer has a slow progression, but a very poor response to treatment and a high mortality rate.

Researchers have known that the broad mechanisms of cancer involve an interplay with the immune system response that includes: recruiting immune cells that influence the tumor microenvironment, escaping from host immunosurveillance and suppression, shifting of the host immune response, and tumor-associated angiogenesis to establish the blood supply.

For the study, the research team first "knocked-out" or removed the CXCR2 gene in mice, and found that the signs typically associated with inflammation were prevented. Furthermore, they demonstrated that CXCR2 dramatically suppressed colonic inflammation and the colitis associated tumor formation, growth and progression in mice.

CXCR2 decorates the outer part of immune cells called myeloid-derived suppressor cells, or MDSCs, that work to block the immune response of killer CD8+ T cells. In the knockout mice, without CXCR2 present, the MDSC cells could no longer migrate from the circulatory system to the colon, dodge the killer CD8+ T cell immune response, and feed the blood supply of the tumor environment. Furthermore, when they transplanted normal MDSC cells (with normal CXCR2) into the knockout mice, tumor formation was restored.

"These results provide the first genetic evidence that CXCR2 is required for recruitment of MDSCs into inflamed colonic mucosa and colitis-associated tumors," said DuBois.

For DuBois, who has devoted his career to unraveling the inflammatory circuitry responsible for colon cancer, the results help connect the dots between the immune system, inflammation and tumor formation and metastasis.

DuBois' team was the first to show that colorectal tumors contained high levels of the enzyme cyclo-oxygenase-2 (COX-2), a key step in the production of pro-inflammatory mediators such as prostaglandin E2 (PGE2). PGE2 triggers production of a CXCR2 molecule that fits into CXCR2 like a baseball into a glove's pocket and activates it. CXCR2, like the pied piper, recruits MDSCs from the bloodstream to sites of inflammation, causing the colon cancer tumors to evade the immune killer CD8+ T immune response.

"Our findings reveal not only how MDSCs are recruited to local inflamed tissues and tumor microenvironment and how local MDSCs contribute to colorectal cancer progression, but now also provide a rationale for developing new therapeutic approaches to subvert chronic inflammation- and tumor-induced immunosuppression by using CXCR2 antagonists and neutralizing antibodies," said DuBois.


'/>"/>

Contact: Joe Caspermeyer
joseph.caspermeyer@asu.edu
480-258-8972
Arizona State University
Source:Eurekalert  

Related medicine news :

1. Princeton study: Military children and their families remain an invisible subculture
2. Hope for transplant patients as study finds key to organ scarring
3. Searchen Releases Statement on Celebrity and Athletic Endorsement Study
4. Investigational Drug Effective in Treating Iron Deficiency in Chronic Kidney Disease Patients on Dialysis: Study
5. Journal of Traumatic Stress Study Analyzes Psychological Effects of Marathon Bombing on Boston-Area Veterans with Post-Traumatic Stress Disorder (PTSD)
6. In animal study, cold turkey withdrawal from drugs triggers mental decline
7. TGen-led study reveals TWEAK-Fn14 as key drug target
8. Study using stem cells to improve organ transplantation to receive $12 million
9. FDA awards $2.25M grant to study immunosuppresive drug in high-risk patients
10. Study finds that Americans want doctors guidance on genetic test results
11. New study assesses injuries seen in the emergency department to children of teenage parents
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study finds key link responsible for colon cancer initiation and metastasis
(Date:12/5/2016)... ... ... “Life Will Never Be The Same” is a fictional tale about growing up with ... is the creation of published author, Kim T. Briggs, a self-described “big kid” who ... religion and philosophy from Judson University in Elgin, Illinois. Having written numerous Christian drama ...
(Date:12/5/2016)... ... ... has joined the Retina Group of New York (RGONY) specializing in uveitis and ... and has been providing tertiary medical and surgical retinal care on Long Island for over ... peers. Growing up in a family of doctors, Dr. Shah emulated the role of ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... excellent way to ensure moisture measurements are consistently correct. However, regular performance ... , Now, METTLER TOLEDO offers a solution: SmartCal™ . This innovative ...
(Date:12/5/2016)... OH (PRWEB) , ... December 05, 2016 , ... ... engineering solution called the CardioQuick Patch® significantly improves the reproducibility and accuracy of ... in various healthcare settings. , Over the last 60 years, studies have ...
(Date:12/4/2016)... ... December 03, 2016 , ... "Perfect Harmony comes with 20 ... FCPX editors to create professional looking video in a matter of minutes," said ... a beautifully designed 3D environment for placing in personal media. Twenty pre-made layouts ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... PharmaBoardroom today releases its new 70 page ... ... companies, investors, policymakers, and stakeholders crucial insight into Switzerland ... , home to some of the world,s most important international health institutions ... Roche, and with a number one ranking globally in terms of ease ...
(Date:12/4/2016)... SAN DIEGO , Dec. 3, 2016 Johnson ... filed on behalf of purchasers of Zimmer Biomet Holdings, Inc. ... September 7, 2016 through October 31, 2016 (the "Class Period"). ... It designs, manufactures, and markets orthopaedic reconstructive products, such as ... ...
(Date:12/4/2016)... A highly innovative, personalized cell-based treatment for a high-risk form of the ... from Children,s Hospital of Philadelphia today reported new ... (ALL). The physician-scientists presented findings at the annual meeting of ... . Continue Reading ... ...
Breaking Medicine Technology: